 |
市场调查报告书
商品编码
1532415
非小细胞肺癌市场：按类型、治疗、最终用户、地区Non-Small Cell Lung Cancer Market, By Type, By Treatment, By End User, By Geography |
||||||
价格
简介目录
预计2024年全球非小细胞肺癌市场规模为261亿美元，预计2031年将达491.1亿美元，2024年至2031年复合年增长率为9.4%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 261亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测 2024-2031 年复合年增长率： | 9.40% | 2031年价值预测 | 491.1亿美元 |
图：2024 年按地区分類的非小细胞肺癌市场份额 (%)
非小细胞肺癌 (NSCLC) 是最常见的肺癌，约占所有肺癌的 85%，是全球癌症相关死亡的主要原因之一。全球非小细胞肺癌市场的成长是由吸烟习惯和环境污染的增加、先进标靶治疗方案的研发活动的增加以及对标靶和个人化治疗的需求不断增长等因素所推动的。然而，高昂的处理成本阻碍了市场的成长。
市场动态：
全球非小细胞肺癌市场成长的驱动力是已开发国家和新兴国家吸烟习惯的增加、环境污染水平的上升以及人口老化。据世界卫生组织称，全球每年报告约 180 万新发肺癌病例，其中大多数为非小细胞肺癌 (NSCLC)。标靶治疗和癌症治疗方法的进步为市场相关人员提供了机会。然而，与标靶治疗相关的高成本以及低收入国家缺乏认识正在阻碍市场成长。此外，测试过程中药物失败的风险也会对研发活动产生负面影响。
本研究的主要特点
- 该报告对全球非小细胞肺癌市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。
- 它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
- 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球非小细胞肺癌市场的主要企业进行概况分析。
- 该报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球非小细胞肺癌市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 透过用于分析全球非小细胞肺癌市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 机会
- 影响分析
- 市场趋势
- 主要进展
- 监管场景
- 收购和合作场景
- 资金筹措和投资
- PEST分析
- 波特的分析
第四章全球非小细胞肺癌市场：COVID-19 大流行的影响
- 整体影响
- 政府倡议
- COVID-19 对市场的影响
第五章全球非小细胞肺癌市场：依类型划分，2019-2031
- 腺癌
- 鳞状细胞癌
- 大细胞癌
- 大细胞神经内分泌肿瘤
第六章 全球非小细胞肺癌市场：依治疗方法分类，2019-2031 年
- 化疗
- 标靶治疗
- Bevacizumab（Avastin）
- Necitumumab（Portrazza）
- Ramucirumab（CYRAMZA）
- 免疫疗法
- 纳武单抗（Opdivo）
- Atezolizumab（TECENTRIQ）
- 其他的
第 7 章 全球非小细胞肺癌市场：依最终使用者分类，2019-2031 年
- 医院
- 居家照护
- 专科诊所
- 其他的
第八章全球非小细胞肺癌市场：依地区划分，2019-2031
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
第9章 竞争格局
- 公司简介
- F. Hoffmann-La Roche Ltd
- Honeywell International Inc.
- AstraZeneca PLC
- Merck &Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson &Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
第10章分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第11章 章节
- 参考
- 调查方法
简介目录
Product Code: CMI241
Global non-small cell lung cancer market is estimated to be valued at USD 26.10 Bn in 2024 and is expected to reach USD 49.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 26.10 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 9.40% | 2031 Value Projection: | US$ 49.11 Bn |
Figure. Non-Small Cell Lung Cancer Market Share (%), By Region 2024
Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.
Market Dynamics:
Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.
Key features of the study:
- This report provides in-depth analysis of the global non-small cell lung cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.
Detailed Segmentation-
- By Type
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Large Cell Neuroendocrine Tumors
- Treatment
- Chemotherapy
- Targeted Therapy
- Bevacizumab
- Necitumumab
- Ramucirumab
- Immunotherapy
- Nivolumab
- Atezolizumab
- Others
- End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Hoffmann-La Roche Ltd
- Honeywell International Inc.
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Non-Small Cell Lung Cancer Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Non-Small Cell Lung Cancer Market, By Type, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Adenocarcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Squamous Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Large Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Large Cell Neuroendocrine Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Non-Small Cell Lung Cancer Market, By Treatment, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Bevacizumab (Avastin)
- Necitumumab (Portrazza)
- Ramucirumab (Cyramza)
- Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Non-Small Cell Lung Cancer Market, By End User, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospitals
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Home Care
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Non-Small Cell Lung Cancer Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Honeywell International Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca PLC
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- F. Hoffmann-La Roche Ltd
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. Section
- References
- Research Methodology
- About Us and Sales Contact
